🔴 MetaVia Inc. is trading 6% down today after clinical data on its obesity drug candidate

MetaVia Inc. is trading approximately 6% down at $2.42 in after-hours trading as investors digest clinical data for its dual GLP-1/glucagon candidate, DA-1726.

• The company presented late-breaking abstracts for the obesity and diabetes treatment at the American Diabetes Association’s 2026 Scientific Sessions.
• The downward move follows a period of profit-taking after the stock gained 4.9% to close at $2.57 on June 5.